<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03879473</url>
  </required_header>
  <id_info>
    <org_study_id>CV185-614</org_study_id>
    <nct_id>NCT03879473</nct_id>
  </id_info>
  <brief_title>Direct Oral Anticoagulant Management for Cardiac Device Implantation</brief_title>
  <acronym>StimAOD</acronym>
  <official_title>Influence of Peri-procedural Management of Direct Oral Anticoagulants on the Incidence of Pocket Hematoma in Patients Undergoing Cardiac Rhythm Device Implantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Necker Enfants Malades</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Necker Enfants Malades</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Each year, tens of thousands of cardiac rhythm devices including pacemaker (PM) or
      implantable cardioverter-defibrillator (ICD) are implanted in France. More than 25% of
      patients undergoing cardiac device implantation receive long-term anticoagulation therapy,
      that increases the incidence of pocket hematoma with potential serious consequences for
      patients. Although more and more patients receive direct oral anticoagulants (DOACs), limited
      data currently exist on the perioperative management of DOAC-treated patients undergoing
      cardiac device implantation and the optimal strategy remains unclear. Especially, the time of
      DOAC resumption after the procedure is controversial.

      We hypothesize that the time of DOAC resumption is the main risk factor of bleeding event in
      DOAC-treated patients undergoing cardiac device implantation, that is to say that a delayed
      DOAC resumption &gt; 48 hours following the procedure will reduce pocket hematoma incidence
      compared with an early resumption, ≤ 48 hours, without increasing thromboembolic events. We
      propose here an observational multicentre national study to find out the optimal strategy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2019</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Anticipated">February 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>number of patients with clinically significant pocket hematoma</measure>
    <time_frame>30 +/- 5 days</time_frame>
    <description>hematoma requiring reoperation, and/or resulting in prolongation of hospitalization, and/or requiring interruption of all anticoagulation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of patients with thromboembolic event</measure>
    <time_frame>30 +/- 5 days</time_frame>
    <description>transient ischemic attack, stroke, peripheral embolus, venous thromboembolism</description>
  </secondary_outcome>
  <enrollment type="Anticipated">680</enrollment>
  <condition>Anticoagulant, Perioperative</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Inclusion Criteria:

          -  receiving DOAC (apixaban, rivaroxaban, dabigatran) for stroke prevention in atrial
             fibrillation at least 5 days prior to enrolment

          -  undergoing a cardiac rhythm device implantation (implantation or replacement of PM (1
             or 2 leads) and ICD (1or 2 leads) with or without cardiac-resynchronization therapy

          -  informed
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  receiving DOAC (apixaban, rivaroxaban, dabigatran) for stroke prevention in atrial
             fibrillation at least 5 days prior to enrolment

          -  undergoing a cardiac rhythm device implantation (implantation or replacement of PM (1
             or 2 leads) and ICD (1or 2 leads) with or without cardiac-resynchronization therapy

          -  informed
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne-Céline Martin, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>INSERM 1140</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nassima Oukkal</last_name>
    <phone>01 56 09 20 00</phone>
    <email>nassima.oukkal-ext@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nassima Oukkal</last_name>
    <email>nassima.oukkal-ext@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>HEGP</name>
      <address>
        <city>Paris</city>
        <zip>75000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nassima Oukkal</last_name>
    </contact>
    <investigator>
      <last_name>Eloi Marijon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 14, 2019</study_first_submitted>
  <study_first_submitted_qc>March 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 18, 2019</study_first_posted>
  <last_update_submitted>March 15, 2019</last_update_submitted>
  <last_update_submitted_qc>March 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Institut Necker Enfants Malades</investigator_affiliation>
    <investigator_full_name>Anne-Céline MARTIN</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

